Dr Aymen I Idris
Department of Oncology and Metabolism
+44 114 215 9051
Full contact details
Department of Oncology and Metabolism
The Medical School
Beech Hill Road
I am a Pharmacologist and Senior Lecturer in pharmacology at the Department of Oncology & Metabolism, University of Sheffield (England, UK). My interest in musculoskeletal pharmacology began in 2000 when I joined Professor Stuart H. Ralston's group at the University of Aberdeen (Scotland, UK), where I obtained a PhD in Medicine and underwent my early postdoctoral training.
One of my particular areas of interests during this period was the effect of cannabis-like substances on bone biology and pharmacology. In this area, I carried out significant research on the skeletal effects of endocannabinoids and their receptors on bone biology with publications in Nature Medicine, Cell Metabolism and Aging Cell.
I also conducted research into the role of the NFkB signalling pathway in bone disease resulting in a number of publications in Endocrinology, FASEB J and JBMR, and a series of patents of a novel family of NFkB inhibitors, which exhibit anti-resorptive, anti-inflammatory and anti-tumour properties. Between 2010 and 2013, I held a position of non-clinical lecturer in cancer associated bone disease at Edinburgh Cancer Research UK Centre at the University of Edinburgh (Scotland, UK).
During this period, my group developed a number of model systems to study tumour – immune - bone cell interactions in vitro, ex vivo and in vivo, a system we have successfully utilized in our research and publications in Cancer Letters, Oncotarget and J.Bio.Chem.
I graduated with a BSc (Hons) degree from University of Sunderland, UK, and I obtained an MSc in Pharmacology working in Professor G. H. Hawksworth’s laboratory at the university of Aberdeen.
- Research interests
The primary interest of my group is pharmacology of inflammation. The specific aims of our research are to:
- uncover novel druggable pro-inflammatory transduction pathways essential for the regulation of cancer – immune - bone cell interactions, and guided by these studies
- design and test novel therapeutic agents - alone or in combination with drugs in clinical practice - for the treatment of chronic inflammation associated with bone diseases and cancer.
- Targeting of IKK-Epsilon alone or in combination with chemotherapeutic drugs for breast cancer treatment.
- Regulation of adipocyte – cancer cell crosstalk by NFkB signalling.
- Role of TRAFs/NFkB signalling in inflammation associated with metastatic cancer.
- Role of RANK/NFkB signalling in cancer cell behaviour in bone.
- Regulation of bone – immune – malignant cell interactions by the Endocannabinoid/NFkB axis.
- Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis. Cancer Letters, 488, 27-39.
- JZL184, a monoacylglycerol lipase inhibitor, induces bone loss in a multiple myeloma model of immunocompetent mice. Calcified Tissue International. View this article in WRRO
- Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice. EBioMedicine, 44, 452-466. View this article in WRRO
- Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer. Cancer Letters, 450, 76-87. View this article in WRRO
- Pharmacological Inhibition of NFκB Reduces Prostate Cancer Related Osteoclastogenesis In Vitro and Osteolysis Ex Vivo. Calcified Tissue International, 1-12. View this article in WRRO
- Raman spectroscopy as a predictive tool for monitoring osteoporosis therapy in a rat model of postmenopausal osteoporosis. Journal of Materials Science: Materials in Medicine, 30(2).
- Bidirectional regulation of bone formation by exogenous and osteosarcoma-derived Sema3A. Scientific Reports, 8(1). View this article in WRRO
- Regulation of breast cancer induced bone disease by cancerspecific IKKβ. Oncotarget, 9(22), 16134-16148. View this article in WRRO
- Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis. Calcified Tissue International. View this article in WRRO
- Raman spectroscopy predicts the link between claw keratin and bone collagen structure in a rodent model of oestrogen deficiency. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1864(2), 398-406. View this article in WRRO
- TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis. Scientific Reports, 8(1). View this article in WRRO
- Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis. Cancer Letters, 410, 180-190. View this article in WRRO
- Combined deficiency of the Cnr1 and Cnr2 receptors protects against age‐related bone loss by osteoclast inhibition. Aging Cell, 16(5), 1051-1061. View this article in WRRO
- Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor. Pharmacological Research, 119, 391-403. View this article in WRRO
- Bone Cell-autonomous Contribution of Type 2 Cannabinoid Receptor to Breast Cancer-induced Osteolysis. Journal of Biological Chemistry, 290(36), 22049-22060.
- Rodent models of osteoporosis. BoneKEy Reports, 3.
- Modulation of Strain-Specific Differences in Gene Expression by Cannabinoid Type 2 Receptor Deficiency. Calcified Tissue International, 94(4), 423-432.
- Genetic Background Modifies the Effects of Type 2 Cannabinoid Receptor Deficiency on Bone Mass and Bone Turnover. Calcified Tissue International, 94(3), 259-268.
- Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis. Journal of Bone and Mineral Research, 28(5), 1229-1242.
- Role of cannabinoids in the regulation of bone remodeling. Frontiers in Endocrinology, 3. View this article in WRRO
- Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo. British Journal of Pharmacology, 165(6), 1914-1925.
- The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease. BoneKEy Reports, 1, 224-224.
- Ovariectomy/Orchidectomy in Rodents, 545-551.
- Analysis of Signalling Pathways by Western Blotting and Immunoprecipitation, 223-232.
- The Type 2 Cannabinoid Receptor Regulates Bone Mass and Ovariectomy-Induced Bone Loss by Affecting Osteoblast Differentiation and Bone Formation. Endocrinology, 152(6), 2141-2149.
- The promise and dilemma of cannabinoid therapy: Lessons from animal studies of bone disease. IBMS BoneKEy, 8(2), 84-95.
- The Biphenyl-Carboxylate Derivative ABD328 is a Novel Orally Active Antiresorptive Agent. Calcified Tissue International, 87(6), 525-532.
- Small molecule inhibitors of IκB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy‐induced bone loss in vivo. The FASEB Journal, 24(11), 4545-4555.
- Cannabinoids and Bone: Friend or Foe?. Calcified Tissue International, 87(4), 285-297.
- The type 2 cannabinoid receptor protects against age-related bone loss and ovariectomy induced bone loss by stimulating bone formation. Bone, 47, S42-S43.
- Corrigendum to “ABD56 causes osteoclast apoptosis by inhibiting the NFκB and ERK pathways” [Biochem. Biophys. Res. Commun. 371 (2008) 94–98]. Biochemical and Biophysical Research Communications, 395(2), 289-289.
- The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo. Bone, 46(4), 1089-1099.
- Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies. Current Neuropharmacology, 8(3), 243-253.
- Cannabinoid Receptor Type 1 Protects against Age- Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells. Cell Metabolism, 10(2), 139-147.
- Pharmacologic inhibitors of I B kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Molecular Cancer Therapeutics, 8(8), 2339-2347.
- Cannabinoid receptor type 1 protects against age-related bone loss by regulating osteoblast and adipocyte differentiation of bone marrow stromal cells. Bone, 44, S222-S222.
- A small molecule inhibitor of RANKL- and TNF-induced signalling prevents ovariectomy-induced bone loss and inflammation in collagen induced arthritis. Bone, 44, S244-S245.
- The type 2 cannabinoid receptor (CB2) protects against age-related osteoporosis by affecting bone formation and CB2 agonists exhibit anabolic activity in vivo. Bone, 44, S219-S219.
- Profile analysis of metaphyseal trabecular bone in rodent ovariectomy models reveals a bimodal dose-dependent response to administered bone active agents. Bone, 44, S155-S156.
- NOVEL SMALL MOLECULE INHIBITORS OF TNF- AND RANKL-SIGNALING PREVENT COLLAGEN INDUCED ARTHRITIS. RHEUMATOLOGY, 48, I40-I40.
- β2-Adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms. Archives of Biochemistry and Biophysics, 482(1-2), 96-103.
- The nitrosylated flurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action. European Journal of Pharmacology, 602(2-3), 215-222.
- Identification of Novel Biphenyl Carboxylic Acid Derivatives as Novel Antiresorptive Agents that Do Not Impair Parathyroid Hormone-Induced Bone Formation. Endocrinology, 150(1), 5-13.
- Role of cannabinoid receptors in bone disorders: Alternatives for treatment. Drug News and Perspectives, 21(10), 533-540.
- Regulation of Bone Mass, Osteoclast Function, and Ovariectomy-Induced Bone Loss by the Type 2 Cannabinoid Receptor. Endocrinology, 149(11), 5619-5626.
- ABD56 causes osteoclast apoptosis by inhibiting the NFκB and ERK pathways. Biochemical and Biophysical Research Communications, 371(1), 94-98.
- Beta-2 adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms. Bone, 42, S34-S35.
- Aminobisphosphonates Cause Osteoblast Apoptosis and Inhibit Bone Nodule Formation In Vitro. Calcified Tissue International, 82(3), 191-201.
- Small molecule inhibitors of IKK-dependent signalling inhibit osteoclast formation in vitro and ovariectomy-induced bone loss in vivo. CALCIFIED TISSUE INTERNATIONAL, 82, S32-S32.
- Cannabinoid receptor antagonists inhibit osteoclast formation in vitro and ovariectomy-induced bone loss in vivo through the CB1 and CB2 receptors. CALCIFIED TISSUE INTERNATIONAL, 82, S31-S31.
- The IKK inhibitors celastrol and parthenolide inhibit breast cancer cell proliferation and migration in vitro and osteolytic bone metastasis in vivo. CALCIFIED TISSUE INTERNATIONAL, 82, S49-S49.
- The novel biphenyl ketone ABD345 inhibits Nf-kappa-B activation, inflammation and joint destruction in collagen induced arthritis. CALCIFIED TISSUE INTERNATIONAL, 82, S136-S136.
- Cannabinoid receptor 2 selective agonists stimulate osteoclast formation in vitro but act as anabolic agents in vivo by stimulating bone formation. CALCIFIED TISSUE INTERNATIONAL, 82, S118-S118.
- Bidirectional regulation of peak bone mass and age-related bone loss by the type I cannabinoid receptor. CALCIFIED TISSUE INTERNATIONAL, 82, S57-S57.
- A Comparison between the Effects of Hydrophobic and Hydrophilic Statins on Osteoclast Function In Vitro and Ovariectomy-Induced Bone Loss In Vivo. Calcified Tissue International, 81(5), 403-413.
- Nitrogen-containing bisphosphonates inhibit bone mineralization in vitro via a mechanism independent of inhibition of protein prenylation. CALCIFIED TISSUE INTERNATIONAL, 80, S79-S79.
- Biphenylcarboxylates inhibit bone resorption in vitro and ovariectomy induced bone loss in vivo without impairing PTH induced bone formation. CALCIFIED TISSUE INTERNATIONAL, 80, S28-S28.
- Small molecule inhibitors of TRAF-dependent signaling as anti resorptive and anti-rheumatic drugs. CALCIFIED TISSUE INTERNATIONAL, 80, S33-S33.
- Cannabinoid receptor agonists are potential bone anabolic agents which stimulate bone formation in vitro and increase bone mass in vivo. CALCIFIED TISSUE INTERNATIONAL, 80, S32-S32.
- Development and Characterization of Biphenylsulfonamides as Novel Inhibitors of Bone Resorption. Journal of Medicinal Chemistry, 49(25), 7487-7492.
- Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nature Medicine, 11(7), 774-779.
- Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors.. J Bone Miner Res, 19(10), 1651-1660.
- The flurbiprofen derivatives HCT1026 and HCT1027 inhibit bone resorption by a mechanism independent of COX inhibition and nitric oxide production. Bone, 35(3), 636-643.
- CANNABINOID RECEPTOR ANTAGONISTS INHIBIT OSTEOCLASTIC BONE RESORPTION IN VITRO AND PREVENT OVARIECTOMY INDUCED BONE LOSS IN VIVO. CALCIFIED TISSUE INTERNATIONAL, 74, S34-S34.
- ABD56 A POTENT INHIBITOR OF BONE RESORPTION, INDUCES OSTEOCLAST APOPTOSIS VIA NFKB AND ERK INHIBITION IN VITRO. CALCIFIED TISSUE INTERNATIONAL, 74, S35-S35.
- Regulation of bone metastasis by the IKK[beta]/FoxO3a axis. Bone Abstracts.
- TRAF2, but not TRAF6, regulates breast cancer induced osteoclastogenesis and osteolysis.. Bone Abstracts.
- Identification of Biphenylcarboxylic Acid Derivatives as a Novel Class of Bone Resorption Inhibitors. Journal of Bone and Mineral Research, 19(10), 1651-1660.
- The Role of NFκB in Bone Remodeling in Health and Cancer, Reference Module in Biomedical Sciences Elsevier
- Analysis of Signaling Pathways by Western Blotting and Immunoprecipitation, Methods in Molecular Biology (pp. 131-143). Springer New York
- Ovariectomy/Orchiectomy in Rodents, Methods in Molecular Biology (pp. 261-267). Springer New York
- Aymen I. Idris Ovariectomy and Orchidectomy in Rodents., Bone Research Protocols. Totowa, NJ: Humana Press
- Analysis of Signalling Pathways in Bone Cells. T, Bone Research Protocols. 2nd ed. Humana Press
Conference proceedings papers
- Genetic inactivation and pharmacological inhibition of IKKβ activity in cancer cells inhibit breast cancer-induced osteoclastogenesis, promotes osteoblast differentiation and prevents osteolysis. Bone, Vol. 50 (pp S51-S51)
- Combined deficiency of the CB1 and CB2 receptors enhances peak bone mass by inhibiting osteoclast differentiation but increases age-related bone loss by promoting adipocyte differentiation and reducing osteoblast differentiation. Bone, Vol. 50 (pp S32-S32)
- A novel small molecule inhibitor of TRAF-dependent signalling inhibits breast cancer-induced osteoclastogenesis and prevents osteolysis. Bone, Vol. 50 (pp S61-S62)
- The novel and selective insulin-like growth factor-1 receptor kinase inhibitor pqip suppresses bone cell function and osteoclast- breast cancer cell cross-talk. Bone, Vol. 48 (pp S257-S257)
- Genetic disruption of both the CB1 and the CB2 receptor in mice enhances trabecular bone mass but reduces cortical bone mass. Bone, Vol. 48 (pp S127-S127)
- The CB2 receptor regulates osteoclast formation, breast cancer cell migration and osteoclast/tumour cell interaction via the PI3 Kinase/AKT pathway. Bone, Vol. 48 (pp S73-S74)
- Identification of hydrogen sulfide releasing compounds as novel antiresorptive and antitumour agents. Bone, Vol. 48(1) (pp S44-S44)
- The novel and selective insulin-like growth factor-1 receptor kinase inhibitor PQIP suppresses bone cell function and osteoclast-breast cancer cell cross-talk in vitro. Bone, Vol. 48(1) (pp S43-S43)
- Peripheral cannabinoid type 2 receptor regulates osteoclast formation, MDA-MB-231 breast cancer cell migration and bone marrow/tumour cell interaction via PI3 kinase/AKT and P38 pathways. Bone, Vol. 48(1) (pp S44-S44)
- A novel profile analysis of metaphyseal trabecular bone reveals a biphasic dose-dependent response to administered bone active agents. Bone, Vol. 43 (pp S19-S19)
- Profile Analysis of Rodent Metaphyseal Trabecular Bone Reveals a Biphasic Dose-Dependent Response To Administered Bone Active Agents. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 23 (pp S220-S220)
- Cannabinoid receptor 2 selective agonists stimulate osteoclast formation in vitro but act as anabolic agents in vivo by stimulating bone formation. Bone, Vol. 42 (pp S31-S31)
- P52. The IKK inhibitors celastrol and parthenolide inhibit breast cancer cell proliferation and migration in vitro and osteolytic bone metastasis in vivo. Cancer Treatment Reviews, Vol. 34 (pp 75-75)
- Rosuvastatin inhibits bone resorption in vitro by inhibiting protein prenylation, and prevents ovariectomy-induced bone loss in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(9) (pp S260-S260)
- Cannabinoid receptor 1 knockout mice have increased bone mass and are protected from ovariectomy-induced bone loss. BONE, Vol. 36 (pp S132-S132)
- ABD56 is a potent inhibitor of RANKL- and TNF-stimulated NF kappa B and ERK activation in vitro. RHEUMATOLOGY, Vol. 44 (pp I36-I36)
- Regulation of osteoclastic bone resorption and bone mass by the cannabinoid receptor 1 pathway.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19 (pp S284-S284)
- Identification of biphenyl-carboxylic acid derivatives as a novel class of bone resorption inhibitors. BONE, Vol. 34 (pp S22-S23)
- Cannabinoid receptor antagonists inhibit osteoclastic bone resorption in vitro and prevent ovariectomy induced bone loss in vivo. BONE, Vol. 34 (pp S22-S22)
- Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions. PCT/GB2004/001958 Appl. 11 Aug 2009.
- Aryl Alkyl Sulfonamides as therapeutic agents for the treatment of bone conditions. PCT/GB2005/002043 Appl. 26 Jan 2006.
- Cannabinoid receptor inverse agonists as therapeutic agents for the treatment of bone disorders. PCT/GB2004/000858 Appl. 16 Sep 2004.
- Recent Trends and Advances in Cancer-Induced Bone Disease. Calcified Tissue International, 102(2), 129-130.
- Teaching interests
- Supervise undergraduates, MSc and PhD students in my laboratory
- Teach a module on hypothesis testing and experimental design in medical research
- Teach and run tutorials on research skills to PhD students
- Act as lead tutor to postgraduate students
- Act as personal academic tutor to medical, MSc and PhD students
- Professional activities
- Founder of the cloud-based software PubFund.
- Editor, Springer Bone Research Protocols, 3rd edition (2019)
- Editor-in-Chief and Founder, HubLE - The IFMRS Learning Environment (2019)
- Associated editor at BoneKEy Reports (2013 - 2017)
- Member of editorial board of Calcified Tissue International
- Editor, Cancer and Bone, Calcified Tissue International (February, 2018)
- Member of British Pharmacological Society (BPS), European Calcified Tissue Society (ECTS), International Bone and Mineral Society (IBMS) and American Society for Bone and Mineral Research (ASBMR).
- Ad hoc reviewer for a number of national and international science journals and research charities.
- Board member of the Calcified Tissue International Society (ECTS, 2010 – 2013).
- Founder of the ECTS Postdoc Gathering and co-founder of ECTS New Investigator Seminar.
- Co-founder and chair of the ECTS New Investigator Committee (2010 – 2013).
- PF SYSTEM Ltd - Founder of PF System Ltd. (Registration No: 11983932), a company established to develop the cloud-based software, PubFund in collaboration with a team of independent software engineers.
- ArthElix Ltd - Founder and shareholder of ArthElix Ltd. (Registration No: 10597512), a company established in 2017 to develop and test novel TRAF/NFkB inhibitors as a novel class of anti-rheumatic and anti-metastatic drugs.
- OSTEORX LIMITED - Co-founder and shareholder of OSTEORX LIMITED (Registration No: SC288265), a company established in 2005 to develop biphenyl-carboxylic acid compounds and their non-hydrolysable derivatives as a novel class of anti-rheumatic drugs. OSTEORX LIMITED and Modern Biosciences plc. have recently entered into an R&D alliance and global option and licence agreement with Janssen Biotech, Inc.
- Young investigator award (ECTS, 2007)
- AMGEN/ECTS Bone Biology Fellowship
- Young investigator award (ECTS, 2006)
- IBMS Young investigator award (ECTS, 2005)
- Young investigator award (ECTS, 2004)
- Frontiers of Skeletal Biology Young investigator award (2002)